Moxifloxacin

SKU: orb1941076

Description

A fourth-generation synthetic fluoroquinolone, broad-spectrum antibacterial agent that is active against both Gram-positive and Gram-negative bacteria; inhibits DNA gyrase and topoisomerase IV.Bacterial Infection Approved(In Vitro):The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation.(In Vivo):Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 151096-09-2
• MW: 401.4314
• Purity: >98% (HPLC)
• Formula: C₂₁H₂₄FN₃O₄
• SMILES: COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
• Target: Antibacterial
• Solubility: 10 mM in DMSO

Bioactivity

• In Vivo:
  Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic. Animal model: 144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia. Dosage: 12 mg/kg. Administration: Intravenous injection; once per day, twice per day, three times per day; for 7 days. Result: Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic.
  Read more...
• In Vitro:
  The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Antibacterial